ASCO 2019
Renal cell carcinoma (RCC) is the most common histologic type of urologic cancer. Worldwide, the age-standardized rate ...
Several therapeutic combinations of immune-oncology (IO) plus vascular endothelial growth factor (VEGF) regimens have ...
Immune Checkpoint Therapy plus Cytoreductive Surgery in mRCC
...
Immune Checkpoint Inhibitor Response in Patients with mRCC
...
Costs of episodes of care in metastatic renal cell carcinoma (mRCC) vary by therapy and treatment decisions have ...
Ipilimumab plus nivolumab is a first-line combination treatment option in patients with metastatic renal cell carcinoma ...
Nivolumab plus ipilimumab was proven superior to sunitinib in objective response rate and overall survival in patients ...
Ronan Flippot, MD, MSc, and colleagues conducted a multicenter, open-label, single arm phase 2 trial of atezolizumab ...
In previous clinical trials of patients with advanced renal cell carcinoma (aRCC), including CheckMate 214, patients ...
The prospective, multicenter study, PAZOREAL, is designed to examine the effectiveness, defined as primary time on ...
In the phase 3 KEYNOTE-426 trial, patients with metastatic renal cell carcinoma (mRCC) had significant improvement in ...
In patients with renal cell carcinoma (RCC) with low tumor burden or slow growing disease, active surveillance is a ...
Researchers reported updated results from cohort A in the KEYNOTE-427 trial during a poster session at the ASCO 2019 ...
Renal function in a large, clinically assessed cohort of childhood cancer survivors was analyzed using data from the St. ...
Treatment for advanced renal cell carcinoma (aRCC) commonly includes immune-oncology therapies and tyrosine kinase ...
There are few data available on gender-related clinical outcomes and safety of treatment of with immune check point ...
Patients with renal cell carcinoma (RCC) or urothelial carcinoma (UC) with clinically significant autoimmune disorders ...
Addition of Apalutamide to ADT Improves Survival in Castration-Resistant Prostate Cancer
...
In previously reported data from the randomized, placebo-controlled, phase III SPARTAN study, researchers found that the ...
The standard of care for smoldering multiple myeloma (SMM), a precursor to MM, is observation. However, a 2015 study ...
Research presented at the 2019 ASCO Annual Meeting found that a balanced, low-fat diet significantly lowers the risk of ...
Entrectinib is a central nervous system (CNS)-penetrant oral inhibitor of tropomyosin receptor kinase (TRK), ROS1, and ...
Immunotherapy has become standardized in treating patients with stage IV non-small cell lung cancer (NSCLC), although ...
Following failure of Bacillus Calmette-Guerin (BCG) for high-grade non–muscle-invasive bladder cancer (NMIBC), there ...
Platinum-based chemotherapy for first-line treatment of metastatic urothelial cancer is typically administered for a ...
Lisocabtagene maraleucel is an investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the ongoing, ...
Increased body mass index (BMI) is typically associated with a risk of estrogen receptor (ER)-positive postmenopausal ...
Survivors of childhood cancer who were treated with chest radiation may be at an increased risk for breast cancer. ...
Many patients with prostate cancer have other conditions or comorbidities that can impact cancer treatment choice. ...
Physiological differences between male and female patients have significant effects on disease management and treatment ...
ASCO is in full swing this week in Chicago. Below are today's top headlines. Check out even more here.
...
Previous research presented at the 2006 ASCO Annual Meeting observed an association between survival and postoperative ...
Many patients with advanced gastroesophageal cancer are older and can be frail. A previous pick-the-winner study ...
Research indicates that just one of five patients with muscle-invasive bladder cancer receive radical cystectomy, ...
High-intensity treatment at end-of-life (EOL) is burdensome and considered low-quality care. Researchers assessed ...
LOXO-292 is an oral and selective investigational novel drug for the treatment of cancers that harbor abnormalities in ...
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased, mainly related to a rise in human ...
Following radical prostatectomy, radiotherapy is the standard salvage treatment. Researchers assessed the impact of ...
In the SOLO1 clinical trial, maintenance olaparib resulted in a significant improvement in progression-free survival ...
Survivors of childhood cancer who were treated with chest radiation may be at an increased risk for breast cancer. ...
While cancer screening rates have improved among minorities, there are still racial and ethnic disparities in diagnosis ...
Asparaginase is often included as part of treatment for acute lymphocytic leukemia (ALL) but is associated with ...
Researchers investigated the risk of developing depression following a prostate cancer work-up and found that men with ...
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.